世界中医药

目的:评价康艾注射液治疗中老年晚期非小细胞肺癌的临床疗效。方法:40例中老年晚期非小细胞肺癌患者随机分为治疗组20例和对照组20例，2组均采用常规对症及营养支持治疗，治疗组在对照组的用药基础上加用康艾注射液60 mL稀释后静滴1次/d，每周期14 d，观察4个周期后肿瘤客观疗效、生活质量、中医临床症状、不良反应方面。结果:治疗组和对照组的肿瘤稳定率分别为70%、55%，但差异无统计学意义(P>0.05)；4个周期后治疗组的体力状况明显优于对照组（P<0.05）；2组患者的中医临床症状疗效比较，治疗组优于对照组，但无统计学意义(P>0.05)；2组患者均未出现明显血液学及消化道毒性。结论：康艾注射液可能会提高中老年晚期非小细胞肺癌患者的体力状况，且无明显不良反应，在这类患者的辅助治疗中存在一定程度的优势。

English Summary:

To observe the clinical effect of Kang’ai injection in treating middle-aged or elderly patients with non-small cell lung cancer(NSCLC). Methods: To randomly divided 40 cases of advanced NSCLC patients into treatment group(20 cases) and control group(20 cases). Both of the two groups were given conventional treatment and nutritional support. Treatment group was also given 60ml of Kang’ai injection intravenous infusion after diluted, once/d, 14d/period. After 4 periods of treatment, to observe the objective effect, living quality, Traditional Chinese Medicine(TCM) clinical symptoms and adverse reaction. Results: The carcinoma stable rate of treatment group is 70% and control group 55%, without statistical significance(P>0.05). After 4 periods of treatment, the physical strength of treatment group is obviously superior to control group(P<0.05). The TCM clinical symptoms curative effect of treatment group is better than control group without tatistical significance(P>0.05). Both of the two groups have no obvious hematologic and archenteric virulence. Conclusion: Kang’ai injection can improve the physical strength of middle-aged or elderly patients with advanced NSCLC, and it has no obvious adverse reaction. Therefore, it could be used in the add-on treatment of NSCLC.

查看全文查看/发表评论下载PDF阅读器